Adoptive immunotherapy prevents prostate cancer in a transgenic animal model

European Journal of Immunology

Volumn 29, Issue 4, 1999, Pages 1127-1138

  Granziero, Luisa ^a,b   Krajewski, Stanislaw ^c   Farness, Peggy ^a   Yuan, Lunli ^a   Courtney, Michele K ^a   Jackson, Michael R ^a   Peterson, Per A ^a   Vitiello, Antonella ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Immunotherapy; Prostate cancer; Transgenic animal model

Indexed keywords

VIRUS T ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HYPERPLASIA; LYMPHOCYTE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCTION; SIMIAN VIRUS 40; TRANSGENIC ANIMAL; TUMOR GROWTH;

EID: 0032954938     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(199904)29:04<1127::AID-IMMU1127>3.0.CO;2-X     Document Type: Article

References (45)

1. Kirby, R. S., Christmas, T. J. and Brawer, M. (Eds.) Prostate Cancer. Times Mirror International Publishers, Limited, London 1996.
2. Yee, C., Riddell, S. R. and Greenberg, P. D., Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 1997. 9: 702-708.
3. Rosenberg, S. A., Yanneli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin. J. Natl. Cancer Inst. 1994. 84: 1159-1166.
4. Berry, S. J. and Isaacs, J. T., Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology 1984. 114: 511-520.
5. Noble, R. L., The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977. 37: 1929-1933.
6. Pollard, M., Spontaneous prostate adenocarcinomas in aged germfree Wistar rats. J. Natl. Cancer Inst. 1973. 51: 1235-1241.
7. Pollard, M. and Luckert, P. H., Autochtonous prostate adenocarcinomas in Lobund-Wistar rats: a model system. Prostate 1987. 11: 219-227.
8. Pollard, M., Luckert, P. H. and Snyder, D. L., The promotional effect of testosterone on induction of prostate-cancer in MNU-sensitized L-W rats. Cancer Lett. 1989. 45: 209-212.
9. Habenicht, U. F., el Etreby, M. F., Lewis, R., Ghoniem, G. and Roberts, J., Induction of metachromasia in experimentally induced hyperplastic/hypertrophic changes in the prostate of the cynomolgus monkey (Macaca fascicularis). J. Urol. 1989. 142: 1624-1626.
10. Thalmann, G. N., Anezinis, P. E., Chang, S. M., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C. and Chung, L. W., Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer [published erratum appears in Cancer Res. 1994, Jul. 15; 54(14):3953]. Cancer Res. 1994. 54: 2577-2581.
11. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J. and Rosen, J. M., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sd. USA 1995. 92: 3439-3443.
12. Greenberg, N. M., DeMayo, F. J., Sheppard, P. C. et al., The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 1994. 8: 230-239.
13. Gingrich, J. R., Baarrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M. and Greenberg, N. M., Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996. 56: 4096-4102.
14. Gleason, D. and The Veterans Administration Cooperative Urologic Research Group, Histologic grading and clinical staging of prostate carcinoma. In Tanenbaum, M. (Ed.) Urologic Pathology: the Prostate. Lea and Febiger, Philadelphia 1977, pp 171-175.
15. Mostofi, F. K. and Price, E. B., Tumors of the prostate. In Firminger, H. I. (Ed.) Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, D. C. 1987, pp 177-179.
16. Ewald, D., Li, M., Efrat, S., Auer, G., Wall, R. J., Furth, P. A. and Henningausen, L., Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996. 273: 1384-1386.
17. Mylin, L. M., Bonneau, R. H., Lippolis, J. D. and Tevethia, J. D., Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 1995. 69: 6665-6677.
18. Vitiello, A., Yuan, L., Chesnut, R. W., Sidney, J., Sothwood, S., Farness, P., Jackson, M. R., Peterson, P. A. and Sette, A., Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J. Immunol. 1996. 157: 5555-5562.
19. Gingrich, J. R., Barrios, R. J., Kattan, M. W., Nahm, H. S., Finegold, M. J. and Greenberg, N. M., Androgemn-independent Prostate Cancer Progression in the TRAMP model. Cancer Res. 1997. 57: 4687-4691.
20. Boon, T. and van der Bruggen, P., Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996. 183: 725-729.
21. Rosenberg, S. A., Kawakami, Y., Robbins, P. F. and Wang, R., Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res. 1996. 70: 145-177.
22. Robbins, P. F. and Kawakami, Y., Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 1997. 8: 628-636.
23. Hara, I., Takechi, Y. and Houghton, A. N., Implicating a Role for Immune Recognition of Self in Tumor Rejection: passive Immunization against the Brown Protein. J. Exp. Med. 1995. 182: 1609-1614.
24. Nossal, G. J., Negative selection of lymphocytes. Cell 1994. 76: 229-239.
25. Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kundig, T. and Hengartner, H., Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 1997. 156: 199-209.
26. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zindernagel, R. M. and Ohashi, P. S., Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T. Cells: Implications for Immunotherapy. J. Exp. Med. 1997. 5: 645-653.
27. Fuchs, E. J. and Matzinger, P., Is cancer dangerous to the immune system? Semin, Immunol. 1996. 8: 271-280.
28. Perry, K. T., Anthony, C. T. and Steiner, M. S., Immunohistochemical localization of TGF beta 1, TFG beta 2 and TGF beta 3 in normal and malignant human prostate. Prostate 1997. 33: 133-140.
29. Melief, C. J. and Kast, W. M., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 1995. 145: 167-177.
30. Gammon, G., Shastri, N., Cogswell, J., Wilbur, S., Sadegh-Nasseri, S., Krzych, U., Miller, A. and Sercarz, E., The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 1987. 98: 53-73.
31. Gammon, G. and Sercarz, E., How some T cells escape tolerance induction. Nature 1989. 342: 183-185.
32. Grasso, Y. Z., Gupta, M. K., Levin, H. S., Zippe, C. D. and Klein, E. A., Combined nested RT-PCR assay for prostate-specific antigen prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res. 1998. 58: 1456-1459.
33. Young, C. Y., Thomas, S., Hogan, K., Charlesworth, M. C., Roche, P. C., Klee, G. G. and Tindall, D. J., Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate suppl. 1996. 7: 17-24.
34. Murphy, G. P., Tino, W. T., Holmes, E. H., Boynton, A. L., Erickson, S. J., Bowes, V. A., Barren, R. J., Tjoa, B. A., Misrock, S. L., Ragde, H. and Kenny, G. M., Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996. 28: 266-271.
35. Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I. and Livingston, P. O., Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 1998. 4: 295-302.
36. Coffey, D. S., Prostate cancer metastasis: talking the walk. Nature Med. 1996. 2: 1305-1306.
37. Bao, L., Loda, M., Janmey, P. A., Stewart, R., AnandApte, B. and Zetter, B. R., Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nature Med. 1996. 2: 1322-1328.
38. Uslu, R., Borsellino, N., Frost, P., Garban, H., Ng, C. P., Mizutani, Y., Belldegrun, A. and Bonavida, B., Chemosensitization of Human Prostate Carcinoma Cell Lines to Anti-Fas-mediated Cytotoxicity and Apoptosis. Clin. Cancer Res. 1997. 3: 963-972.
39. Boon, T., Coulie, P. G. and van den Eynde, B., Tumor antigens recognized by T cells, Immunol. Today. 1997. 18: 267-268.
40. + T cells usable in immunotherapy. Nature Biotech. 1998. 16: 281-285.
41. Salgaller, M. L., Tjoa, B. A., Lodge, P. A., Ragde, H., Kenny, G., Boynton, A. and Murphy, G. P., Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 1998. 18: 109-119.
42. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., Bartholomeuz, R. and Chesnut, R. W., Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995. 95: 341-349.
43. Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987. 162: 156-159.
44. Merrifield, R. B., Automated synthesis of peptides. Science 1965. 150: 178-185.
45. Krajewski, S., Mai, J. K., Krajewska, M., Sikorska, M., Mossakowski, M. J. and Reed, J. C., Upregulation of bax protein levels in neurons following cerebral ischemia. J. Neurosci. 1995. 15: 6364-6376.